LXEONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Lexeo Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$2.76+0.12 (+4.55%)
Close on Oct 19, 2026
- Market cap
- $236.33M
- P/E (TTM)
- –
- Dividend yield
- –
Lexeo Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Lexeo Therapeutics | Industry median |
|---|---|---|
| Market Cap | $226.45M | $166.30M |
| Enterprise Value | -$7.75M | $88.19M |
| PB Ratio | 0.96 | 2.03 |
| P/TBV Ratio | 0.96 | 2.29 |
Income (trailing twelve months)
| Measure | Lexeo Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$95.12M | -$21.40M |
| Pretax Income | -$86.97M | -$14.34M |
| Net Income | -$87.30M | -$22.46M |
| EBITDA | -$94.82M | -$16.91M |
| EPS (Diluted) | -$1.15 | -$0.83 |
Returns
| Measure | Lexeo Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -46.8% | -53.2% |
| Return on Assets (ROA) | -40.5% | -40.9% |
| Return on Invested Capital (ROIC) | -5115.2% | -32.4% |
| Return on Capital Employed (ROCE) | -39.8% | -38.1% |
Balance sheet
| Measure | Lexeo Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $234.20M | $61.43M |
| Net Cash (Debt) | $234.20M | $15.35M |
| Net Cash Per Share | $2.85 | $0.66 |
| Equity (Book Value) | $235.06M | $49.09M |
| Book Value Per Share | $2.86 | $1.37 |
| Tangible Book Value | $235.06M | $23.52M |
| Working Capital | $202.22M | $76.81M |
Financial position
| Measure | Lexeo Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 13.89 | 3.34 |
| Quick Ratio | 14.92 | 2.44 |
| Interest Coverage | -1302.97 | -6.26 |
Cash flow (trailing twelve months)
| Measure | Lexeo Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$88.37M | -$12.35M |
| Capital Expenditures | -$331.00K | -$1.08M |
| Free Cash Flow | -$88.70M | -$20.22M |
| FCF Per Share | -$1.08 | -$0.42 |
Efficiency
| Measure | Lexeo Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$1.48M | -$703.34K |
| Employee Count | 59 | 74 |
Dividends and yields
| Measure | Lexeo Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -38.6% | -23.3% |
| FCF Yield | -39.2% | -8.72% |
| Buyback Yield | -11.2% | -0.59% |
| Shareholder Yield | -11.2% | 0.00% |
Shares
| Measure | Lexeo Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 82,046,300 | 58,127,000 |
| Shares Change (YoY) | 113.1% | 10.9% |
| Shares Change (QoQ) | 6.12% | 0.54% |
| Float | 81,075,400 | 49,136,700 |
| Shares Held by Insiders | 1.18% | 11.6% |
| Shares Held by Institutions | 109.1% | 59.4% |
Scores
| Measure | Lexeo Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | 4.23 | -0.22 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Lexeo Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.